Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

被引：0
|
作者：
Subrahmanyam, Priyanka [1 ]
Dong, Zhiwan [2 ,3 ]
Gusenleitner, Daniel [2 ,3 ]
Giobbie-Hurder, Anita [2 ,3 ]
Severgnini, Mariano [2 ,3 ]
Zhou, Jun [2 ,3 ]
Manos, Michael [2 ,3 ]
Maecker, Holden [1 ]
Hodi, F. Stephen [2 ,3 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA 02115 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka B.
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Eastman, Lauren M.
    Maecker, Holden T.
    Hodi, F. Stephen
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [2] CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients
    Goltz, Diane
    Gevensleben, Heidrun
    Vogt, Timo J.
    Dietrich, Joern
    Golletz, Carsten
    Bootz, Friedrich
    Kristiansen, Glen
    Landsberg, Jennifer
    Dietrich, Dimo
    [J]. JCI INSIGHT, 2018, 3 (13):
  • [3] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy
    Rogiers, Aljosja
    Dimitriou, Florentia
    Lobon, Irene
    Harvey, Catriona
    Vergara, Ismael A.
    da Silva, Ines Pires
    Lo, Serigne N.
    Scolyer, Richard A.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [5] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    [J]. BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [6] Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
    Gide, Tuba Nur
    Quek, Camelia
    Madore, Jason
    Menzies, Alexander M.
    Dent, Rebecca
    Carlino, Matteo S.
    Guminski, Alex
    Saw, Robyn
    Thompson, John F.
    Wilmott, James S.
    Scolyer, Richard A.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [7] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    [J]. JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [8] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
    da Silva, Ines Pires
    Li, Isabel
    Ugurel, Selma
    Serra-Bellver, Patricio
    Andhale, Avanti
    Burnette, Hannah
    Aya, Francisco
    Conway, Jordan W.
    Braden, Jorja
    Carlino, Matteo S.
    Menzies, Alexander M.
    Weichenthal, Michael
    Mohr, Peter
    Gutzmer, Ralf
    Arance, Ana M.
    Johnson, Douglas B.
    Lorigan, Paul
    Schadendorf, Dirk
    Lo, Serigne N.
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2024, 205
  • [9] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [10] Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy
    Holmes, Zachary
    Courtney, Ashling
    Hiong, Alison
    [J]. BMJ CASE REPORTS, 2022, 15 (08)
12345